Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018083103) [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/083103 International Application No.: PCT/EP2017/077920
Publication Date: 11.05.2018 International Filing Date: 31.10.2017
IPC:
C07D 487/04 (2006.01) ,C07D 451/02 (2006.01) ,A61K 31/519 (2006.01) ,A61P 25/00 (2006.01)
[IPC code unknown for C07D 487/04][IPC code unknown for C07D 451/02][IPC code unknown for A61K 31/519][IPC code unknown for A61P 25]
Applicants:
JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30 2340 Beerse, BE
Inventors:
VAN ROOSBROECK, Yves, Emiel, Maria; BE
BUIJNSTERS, Peter, Jacobus, Johannes, Antonius; BE
TRESADERN, Gary; ES
JACOBY, Edgar; BE
OEHLRICH, Daniel; BE
GIJSEN, Henricus, Jacobus, Maria; BE
Agent:
QUAGHEBEUR, Luc; BE
Priority Data:
16196943.102.11.2016EP
Title (EN) [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS
(FR) COMPOSÉS DE [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE EN TANT QU'INHIBITEURS DE PDE2
Abstract:
(EN) The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.
(FR) La présente invention concerne de nouveaux dérivés de [1,2,4]triazolo[1,5-a]pyrimidin-yl utilisés comme inhibiteur de la phosphodiestérase 2 (PDE2). L'invention concerne aussi des compositions pharmaceutiques comprenant ces composés, des procédés de préparation de ces composés et compositions, et l'utilisation de ces composés et compositions pour la prévention et le traitement de troubles dans lesquels PDE2 est impliquée, comme les troubles neurologiques et psychiatriques.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)